A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …

T cells have the capacity to eradicate diseased cells, but tumours present considerable
challenges that render T cells ineffectual. Cancer cells often make themselves …

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed
and/or refractory pre–B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a …

We explored the utility of targeting anaplastic lymphoma kinase (ALK), a cell surface
receptor overexpressed on pediatric solid tumors, using chimeric antigen receptor (CAR) …

Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable outcomes
in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute …

Many tumors overexpress tumor-associated antigens relative to normal tissue, such as
EGFR. This limits targeting by human T cells modified to express chimeric antigen receptors …

Progress in adoptive T-cell therapy for cancer and infectious diseases, is hampered by the
lack of readily available, antigen-specific, human T lymphocytes. Pluripotent stem cells could …

The effectiveness of chimeric Ag receptor (CAR)–transduced T (CAR-T) cells has been
attributed to supraphysiological signaling through CARs. Second-and later-generation …

One important purpose of T cell engineering is to generate tumor-targeted T cells through
the genetic transfer of antigen-specific receptors, which consist of either physiological, MHC …

Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …